Table 1 Clinical characteristics of individuals included in the study at baseline.
From: Cell-free DNA concentration and fragment size as a biomarker for prostate cancer
Healthy N = 34 | Localized N = 112 | mCRPC N = 122 | |
|---|---|---|---|
Age (years) | |||
Median ± IQR | 60 ± 17 | 65 ± 10 | 71 ± 9 |
Range | 41–74 | 43–78 | 47–91 |
Pathologic Gleason* | |||
6 | – | 6 | – |
7 | – | 75 | – |
8–10 | – | 30 | – |
Pathologic stage | |||
Organ confined (pT2) | – | 46 | – |
Not organ confined (pT3, pT4) | – | 66 | – |
Extraprostatic extension (pT3a) | – | 43 | – |
Seminal vesicle invasion (pT3b) | – | 15 | – |
Lymph node involvement (N1) | – | 17 | – |
PSA (ng/mL) | |||
Median ± IQR | – | 6.9 ± 7.4 | 50.8 ± 128 |
Range | – | 1.21–70.0 | 0–3007 |
cfDNA concentration (ng/mL)† | |||
Median ± IQR | 7.9 ± 4.0 | 6.7 ± 5.8 | 13.8 ± 28.1 |
Range | 0.29–16.9 | 1.22–53.9 | 1–1380 |
cfDNA fragment size (bp) | |||
Median ± IQR | 177.5 ± 29.5 | 173 ± 6 | – |
Range | 142–265 | 135–280 | – |
